Researcher Spotlight: Erin Mulvey, MD Weill Cornell Medical College Diffuse large B-cell lymphoma (DLBCL) and follicularlymphoma (FL) are the two most common types of non-Hodgkin lymphoma, with one categorized as aggressive (fast-growing) and one considered indolent (slow-growing), respectively.First-line treatment for DLBCL…
Researcher Spotlight: Luis Malpica Castillo, MD The University of Texas M.D. Anderson Cancer Center Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, generally incurable type of non-Hodgkin lymphoma (NHL) caused by infection with the human T-cell leukemia virustype 1 (HTLV-1). This…
Researcher Spotlight: Arushi Khurana, M.B.B.S Mayo Clinic, Rochester, MN More than two-thirds of the newly diagnosed Diffuselarge B-cell lymphoma (DLBCL) patients are excluded from participating in clinical trials, without considering the structural and attitudinal barriers that preclude clinical trial participation. Over the…
Researcher Spotlight: P. Connor Johnson, MD Massachusetts General Hospital Older adults with fast-growing lymphomas are often treated with chemotherapy which has the potential to cure some of these diseases. However, understanding which patientswill have serious side effects, complications, and loss…
Researcher Spotlight: David A. Bond, MD The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital Diffuse large B-cell lymphoma (DLBCL) is the mostcommon type of non-Hodgkin lymphoma (NHL). SinceDLBCL can advance quickly, it usually requires immediatetreatment, which…
Researcher Spotlight: Nicole Prutsch, PhD Dana-Farber Cancer Institute T-cell lymphomas represent a heterogeneous group of peripheral and cutaneous non-Hodgkin lymphomas (NHL) with a range of unmet clinical needs. Anaplastic large cell lymphoma (ALCL) is a CD30+ subtype of non-Hodgkin T-cell…
Researcher Spotlight: Richa Kapoor, PhD Perelman School of Medicine, University of Pennsylvania T-cell lymphomas are aggressive cancer types that exhibit clinical and genetic heterogeneity, and current therapies do not incorporate personalized medicine opportunities. Research has shown that cutaneous T-cell lymphoma…
Researcher Spotlight: Hannah Isles, PhD Weill Cornell Medicine Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). The recentidentification of DLBCL patient subgroups featuring distinct DNA mutation profiles have provided researchers with new opportunities to treat…
Researcher Spotlight: Rui Guo, PhD Brigham and Women’s Hospital, Harvard Medical School Epstein-Barr virus (EBV) was the first virus found to causeBurkitt lymphoma, a rare and aggressive form of non-Hodgkin lymphoma (NHL). The virus shuts down nearlyall its genes in…
Researcher Spotlight: Kathleen Dixon, PhD University of Minnesota Twin Cities The pioneer monoclonal antibody therapy rituximab(Rituxan) has revolutionized the treatment of B-cell lymphomas. However, patient response to rituximab varies based on numerous factors, including the affinity with which immune cells…
